These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25366687)

  • 1. Progression-free survival: helpful biomarker or clinically meaningless end point?
    Venook AP; Tabernero J
    J Clin Oncol; 2015 Jan; 33(1):4-6. PubMed ID: 25366687
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
    Mooney MM; Schoenfeldt M
    Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
    [No Abstract]   [Full Text] [Related]  

  • 3. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
    Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
    J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Combo Beats Vemurafenib Alone for Colorectal Cancer.
    Cancer Discov; 2017 Mar; 7(3):242. PubMed ID: 28153858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors].
    Bonetti A; Cascinu S; Falcone A; Zaniboni A
    Tumori; 2006; 92(4):suppl 10-43. PubMed ID: 17036537
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis.
    Ilic I; Jankovic S; Ilic M
    PLoS One; 2016; 11(8):e0161912. PubMed ID: 27579775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sound footing or slippery slope? The value of secondary analyses of randomized trials.
    Sargent D; Grothey A
    J Clin Oncol; 2007 Aug; 25(22):3191-3. PubMed ID: 17664465
    [No Abstract]   [Full Text] [Related]  

  • 8. Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting.
    Grothey A
    Clin Adv Hematol Oncol; 2012 Jul; 10(7 Suppl 9):1-24. PubMed ID: 22895157
    [No Abstract]   [Full Text] [Related]  

  • 9. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 10. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
    Krieger G
    Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral fluoropyrimidines in the treatment of colorectal carcinoma].
    Porschen R
    Dtsch Med Wochenschr; 2003 Jun; 128 Suppl 2():S121-3. PubMed ID: 12817344
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combined therapy of rectal tumors: the chemotherapy].
    Di Bartolomeo M; Bajetta E; Beretta E; Buzzoni R
    Tumori; 2001; 87(1 Suppl 1):S31-2. PubMed ID: 11300018
    [No Abstract]   [Full Text] [Related]  

  • 13. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
    Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
    [No Abstract]   [Full Text] [Related]  

  • 14. TAS-102 in metastatic colorectal cancer.
    Burki TK
    Lancet Oncol; 2018 Jan; 19(1):e18. PubMed ID: 29249306
    [No Abstract]   [Full Text] [Related]  

  • 15. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.
    Wainberg Z; Hecht JR
    Clin Colorectal Cancer; 2006 Jan; 5(5):363-7. PubMed ID: 16512997
    [No Abstract]   [Full Text] [Related]  

  • 17. Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
    Saltz L
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):47-50. PubMed ID: 11200149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapy in colorectal carcinoma: more than a theory.
    Pickering L; Rudman S; Ross PJ; Leslie MD
    Colorectal Dis; 2008 Mar; 10(3):209-18; discussion 218-221. PubMed ID: 18257846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of disseminated disease in the patient with bladder cancer.
    Perry JJ; Muss HB
    Urol Clin North Am; 1994 Nov; 21(4):661-72. PubMed ID: 7974898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.